Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer


A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix


Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.


This phase II trial is studying cetuximab to see how well it works in treating patients with persistent or recurrent cervical cancer.

Study Status: Completed


Condition Intervention Phase
Cervical Cancer Biological: cetuximab Phase 2

Verified by Gynecologic Oncology Group July, 2009

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI) identifier: NCT00499031

Study Type: Interventional

Study Design: Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Alessandro Santin, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site